Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Temporary Equity [Member]
Legal Entity [Axis]
Microbot Israel [Member]
Related Party [Axis]
Former Microbot Israel Shareholders [Member]
Property, Plant and Equipment, Type [Axis]
Furniture and Office Equipment [Member]
Research Equipment and Software [Member]
Range [Axis]
Maximum [Member]
Minimum [Member]
Scenario [Axis]
Prior to November 11, 2016 [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
June 2016 Agreements [Member]
Furniture and Office Equipment [Member]
Class of Stock [Axis]
Series A Preferred Shares [Member]
Alpha Capital [Member]
Debt Instrument [Axis]
Secured Note [Member]
Convertible Note [Member]
Merger Agreement [Member]
Series A (2011) [Member]
Series A (2013) [Member]
Series A (2013) [Member]
Series A (2015) [Member]
Series A (2016) [Member]
Series B (2016) [Member]
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Israeli Innovation Authority [Member]
Award Type [Axis]
2013 Through June 30, 2018 [Member]
Technician Research And Development Foundation Limited [Member]
Office Lease Agreement [Member]
Income Statement Location [Axis]
General and Administrative Expense [Member]
Research and Development Expense [Member]
Title of Individual [Axis]
Board of Directors [Member]
Harel Gadot [Member]
Interested and Related Parties [Member]
Income Tax Authority, Name [Axis]
Israel Tax Authority [Member]
Tax Period [Axis]
2016 [Member]
2017 [Member]
From 2018 [Member]
US Tax Authority [Member]
Loan [Member]
Exercise Price Range [Axis]
Exercise Price One [Member]
Exercise Price Two [Member]
Escrow Account [Member]
Officer Lease Agreement [Member]
Purchaser [Member]
Preferred A Shares [Member]
Securities Exchange Agreement [Member]
Investor [Member]
Securities Purchase Agreement [Member]
Series A Convertible Preferred Stock [Member]
Advisors [Member]
Restricted Stock [Member]
Warrant [Member]
Hezi Himelfarb [Member]
Exercise Price Three [Member]
Car Lease Agreements [Member]
Employees [Member]
Employees and Consultant [Member]
Currency [Axis]
NIS [Member]
Consultant [Member]
Exercise Price Four [Member]
Exercise Price Five [Member]
CardioSert Ltd [Member]
Employees and Directors [Member]
Chief Technology Officer [Member]
Plan Name [Axis]
2017 Equity Incentive Plan [Member]
Directors [Member]
Measurement Input Type [Axis]
Measurement Input Price Volatility [Member]
Measurement Input Risk Free Interest Rate [Member]
Product Or Service [Axis]
Grant [Member]
Measurement Input, Exercise Price [Member]
Measurement Input, Price Volatility [Member]
Measurement Input, Risk Free Interest Rate [Member]
Measurement Input, Expected Dividend Rate [Member]
Measurement Input, Expected Term [Member]
Preferred A Shares Microbot Medical Ltd. (Pre - Merger) [Member]
Shareholders' Equity Class [Axis]
Before Reverse Split [Member]
Report Date [Axis]
September 4, 2018 [Member]
September 4, 2018 [Member]
Microbot Israel [Member]
Equity Components [Axis]
2013 Through 2017 [Member]
Cars Lease Agreement [Member]
Hazel Gadot [Member]
Series A Convertible Preferred Stock [Member]
Tax Act [Member]
From January 1, 2018 [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
NIS [Member]
Institutional Holder [Member]
Derivative Instrument [Axis]
2016 Series A and B Warrants [Member]
2011 Series A Warrants [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Filer Category
Entity Small Business Flag
Entity Emerging Growth Company
Entity Ex Transition Period
Trading Symbol
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash and cash equivalents
Restricted cash
Other current assets
Total current assets
Fixed assets, net
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Trade payables
Accrued liabilities
Total current liabilities
Long-term liabilities:
Convertible notes
Derivative warrant liability
Total long term liabilities
Total liabilities
Commitments and contingencies
Temporary equity:
Common stock of $0.01 par value; issued and outstanding: 721,107 shares as of June 30, 2018 and December 31, 2017 and December 31, 2016
Shareholders’ equity:
Preferred stock of $0.01 par value; Authorized: 1,000,000 shares as of June 30, 2018 and December 31, 2017 and December 31, 2016; issued and outstanding: 1,001 and 4,001 and 9,736 shares as of June 30, 2018 and December 31, 2017 and December 31, 2016, respectively
Common stock of $0.01 par value; Authorized: 220,000,000 as of June 30, 2018 and December 31, 2017 and December 31, 2016; issued and outstanding: 2,224,569 and 2,013,193 and 1,067,777 shares as of June 30, 2018, and December 31, 2017 and December 31, 2016, respectively
Additional paid-in capital
Accumulated deficit
Total shareholders' equity
Total liabilities and shareholders' equity
Statement [Table]
Statement [Line Items]
Temporary equity, par value
Temporary equity, shares issued
Temporary equity, shares outstanding
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Reverse stock split
Income Statement [Abstract]
Research and development expenses, net
General and administrative expenses
Operating loss
Financing income (expenses), net
Net loss
Net loss per share, basic and diluted
Weighted-average number of common shares outstanding, basic and diluted
Balance
Balance, shares
Conversion of convertible notes and exercise of warrants issued upon conversion
Conversion of convertible notes and exercise of warrants issued upon conversion, shares
Effect of reverse recapitalization
Effect of reverse recapitalization, shares
Common stock classified as temporary equity
Beneficial Conversion Feature recorded on convertible debt acquired in reverse recapitalization
Transaction costs incurred in reverse recapitalization
Transaction costs incurred in reverse recapitalization, shares
Cancellation of ordinary shares and issuance of preferred shares
Cancellation of ordinary shares and issuance of preferred shares, shares
Share based compensation
Share based compensation, shares
Issuance of common stock
Issuance of common stock, shares
Exercise of options
Exercise of options, shares
Cashless exercise of warrants
Cashless exercise of warrants, shares
Extinguishment of convertible notes and issuance of preferred A shares
Extinguishment of convertible notes and issuance of preferred A shares, shares
Conversion of preferred A shares to common stock
Conversion of preferred A shares to common stock, shares
Shares issued as consideration-vendor
Shares issued as consideration-vendor, shares
Net loss
Balance
Balance, shares
Temporary equity
Statement of Cash Flows [Abstract]
OPERATING ACTIVITIES
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Interest and revaluation of convertible notes, net
Interest and amortization of discount on convertible notes
Share-based transaction costs incurred in reverse recapitalization
Financing loss on debt extinguishment
Changes in fair value of derivative warrant liability
Shares issued as consideration-vendor
Share-based compensation expense
Changes in assets and liabilities:
Other receivables
Other payables and accrued liabilities
Net cash used in operating activities
INVESTMENT ACTIVITIES
Increase in restricted cash
Purchase of property and equipment
Net cash used in investing activities
FINANCING ACTIVITIES
Acquisition of a subsidiary in connection with reverse recapitalization
Transaction costs incurred in reverse recapitalization
Outflow (inflow) in connection with current assets and liabilities acquired in reverse recapitalization, net
Exercise of warrants issued upon conversion of notes
Issuance of common stock, net of issuance costs
Issuance of convertible notes
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash at the beginning of the period
Cash and cash equivalents and restricted cash at the end of the period
Supplemental disclosure of cash flow information:
Non-cash financing transactions:
Cashless exercise of warrants
Conversion of preferred A shares into common shares
Extinguishment of convertible notes in exchange for preferred A shares
Assets acquired (liabilities assumed):
Current assets excluding cash and cash equivalents
Current liabilities
Derivative warrant liability
Convertible note
Reverse recapitalization effect on equity
Cash acquired in connection with reverse recapitalization
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets
Property, Plant and Equipment [Abstract]
Fixed Assets, Net
Payables and Accruals [Abstract]
Accrued Liabilities
Debt Disclosure [Abstract]
Convertible Loan from Shareholders
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Warrant Liabilities
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Equity [Abstract]
Share Capital
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share
Research and Development [Abstract]
Research and Development Expenses, Net
General and Administrative Expense [Abstract]
General and Administrative Expenses
Other Income and Expenses [Abstract]
Finance Expenses, Net
Related Party Transactions [Abstract]
Transactions and Balances With Interested and Related Parties
Income Tax Disclosure [Abstract]
Taxes on Income
Subsequent Events [Abstract]
Subsequent Events
Unaudited Interim Financial Statements
Significant Accounting Policies
Basis of Presentation
Financial Statement in U.S. Dollars
Cash and Cash Equivalents
Fair Value of Financial Instruments
Fixed Assets
Liabilities Due to Termination of Employment Agreements
Basic and Diluted Net Loss Per Share
Research and Development Expenses, Net
Convertible Notes
Share-Based Compensation
Reclassification
Transaction Costs
Income Taxes
Recent Accounting Standards
Estimated Useful Lives of Property and Equipment
Schedule of Other Current Assets
Summary of Fixed Assets, Net
Summary of Accrued Liabilities
Schedule of Carrying Value of Convertible Note
Schedule of Outstanding Warrants Liabilities
Schedule of Valuation of Derivative Warrant Liabilities
Schedule of Fair Value Assumption
Schedule of Liabilities Measured on a Recurring Basis
Summary of Stock Option Activity
Schedule of Stock Options Outstanding
Schedule of Stock Options Valuation Assumptions
Schedule of Basic and Diluted Net Loss Per Share
Schedule of Research and Development Expenses
Schedule of General and Administrative Expenses
Summary of Finance Expenses, Net
Schedule of Related Party Transaction and Balances
Schedule of Deferred Tax Assets
Schedule of Statutory Corporate Tax Rate and Effective Income Tax Rate
Conversion value of shares
Conversion of stock number of common stock issued
Conversion option to purchase common stock
Restricted shares issued
Cash and cash equivalent
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life
Asset consideration
Percentage of severance award
Proceeds from other receivables
Payment of related party
Sale of assets
Deposit in escrow account
Government institutions
Prepaid expenses and others
Total Other current assets
Cost
Accumulated Depreciation
Fixed Assets, net
Employees
Government institution
Other current liabilities
Total Accrued Liabilities
Loan bears interest rate
Secured note principal amount
Principal and accrued interest of note
Debt maturity date
Convertible note, conversion price
Loans receivable
Debt conversion, preferred shares issued
Debt conversion, warrant issued
Exercise price of warrants
Proceeds from exercise of warrant
The loan bears interest rate
Debt, discount rate
Common stock issued in connection with conversion of loan at the merger
Convertible note
Unamortized discount
Accrued interest
Convertible notes
Cashless exercise warrants
Warrant calculation description
Fair value assumption rate
Warrants exercise price
Common shares issued upon exercise of warrants
Warrant outstanding
Number of common stock issued in prior to the merger
Number of Warrant Outstanding, shares
Warrant Exercise Price, Per Share
Warrant Exercisable
Number of Warrant Exercisable, Period
Estimated fair value of warrant liability
Balances beginning
Exercised
Expiration
Changes in fair value
Balances at ending
Cancelled
Share price
Fair value assumption, price
Fair value assumption, percentage
Fair value assumption expected life of up to (years)
Beginning balance
Revaluation of warrants
Exercise warrants
Ending balance
Product and Service [Axis]
Total grants obtained
Royalties payable as percentage of future sales
Lease term
Monthly lease payment
Compensation commitments
Purchase price of Plaintiffs
Loss contingency, damages sought
Initial payment
Number of common shares acquired
Number of common shares acquired, value
Investments
Buy back amount per patent
Monthly consultation fee
Number of options to purchase common stock
Conversion of stock into shares
Authorized capital stock
Ordinary shares, par value
Common stock, shares issued, including temporary equity
Common stock, shares outstanding, including temporary equity
Rights to acquire shares of common stock
Designated preferred stock
Number of common stock shares sold during the period
Common stock price per share
Proceeds from issuance of shares
Placement agent fee
Number of stock options granted
Number of stock option granted as adjustment of reflect merger
Weighted-average exercise price per share, granted
Stock option merger retroactively adjusted exercise price per share
Stock-based employee compensation
Stock option vested term
Number of option exercised
Number of shares issued for services
Number of shares issued for services, value
Number of common shares issued for acquisition
Number of shares issued during period
Common stock shares issued and outstanding reduced during the period
Debt instrument face amount
Loss on extinguishment of convertible note
Repurchase of common stock
Fair market value percentage
Temporary equity value
Reverse stock splits
Number of common stock shares converted upon conversion
Number of Stock Options Outstanding, Outstanding at Beginning Balance
Number of Stock Options Outstanding, Granted
Number of Stock Options Outstanding, Exercised
Number of Stock Options Outstanding, Cancelled
Number of Stock Options Outstanding, Outstanding at Ending Balance
Number of Stock Options Outstanding, Vested and expected-to-vest at end of period
Weighted Average Exercise Price, Outstanding at Beginning Balance
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Outstanding at Ending Balance
Weighted Average Exercise Price, Vested and expected-to-vest at end of period
Aggregate intrinsic value, Stock Options Outstanding at Beginning period
Aggregate intrinsic value, Stock Options Outstanding at End period
Aggregate intrinsic value, Vested and expected-to-vest at end of period
Number of Stock Options Outstanding, Exercised
Per share
Exercise price
Stock options outstanding
Weighted average remaining contractual life
Stock options exercisable
Expected volatility
Risk-free interest
Dividend yield
Expected life of up to (years)
Net loss attributable to shareholders of the company
Net loss attributable to shareholders of preferred shares
Net loss used in the calculation of basic net loss per share
Net loss per share
Weighted average number of common shares
Net loss attributable to shareholders of preferred shares
Net loss per share
Payroll and related expenses
Share-based compensation
Materials
Patents
Office and maintenance expenses
Rent
Professional services
Other
Less: Grants received from IIA
Research and development expense
Share-based compensation
Common shares issued for services
Travel
Marketing expenses
Office and maintenance expenses
Public and Investor Relations
Insurance
Governmental Fees
Other
Total
Bank fees and interest
Change in fair value of derivative warrant liability
Exchange rate differences
Revaluation and interest on convertible loans
Financial expenses, net
Directors fees and insurance
Subcontracted work and consulting
Total
Other accounts payable
Total
Corporate income tax rate
Income tax reconciliation description
Reduced federal tax rate
Net operating losses
Operating loss carryforwards, expiration
Net operating losses carried forward
Net operating loss carry-forward
Total deferred tax assets
Valuation allowance
Net deferred tax asset
Net loss as reported in the statements of operations
Statutory tax rate
Income Tax under statutory tax rate
Change in valuation allowance
Actual income tax
Patent description
Accrued Interest [Member].
Adjusted As Reserve Stock Split [Member]
Advisors [Member]
Alpha Capital [Member]
Automobile Lease Agreement [Member]
Board of Directors [Member]
Buy back amount per patent.
Car Lease Agreements [Member]
CardioSert Ltd [Member]
Cashless exercise of warrants.
Cashless exercise warrants.
Chief Technology Officer [Member]
Common stock shares issued and outstanding reduced during the period.
Common stock, shares issued, including temporary equity.
Common stock, shares outstanding, including temporary equity.
Compensation commitments.
Consultant [Member]
Conversion of convertible notes into preferred A shares.
Conversion value of shares.
Convertible Note [Member]
Decrease [Member]
Definitive Agreement [Member]
Deposit in Escrow Account [Member]
Derivative warrant liabilities.
Exercised.
Derivative warrant liabilities expiration.
Designated preferred stock.
Directors [Member]
Employees and Consultant [Member]
Employees [Member]
Employees and Directors [Member]
Employment Agreement [Member]
Escrow Account [Member]
Exercise Price Five [Member]
Exercise Price Four [Member]
Exercise Price One [Member]
Exercise Price Three [Member]
Exercise Price Two [Member]
Exercise warrants.
Extinguishment of convertible notes and issuance of preferred shares.
Extinguishment of convertible notes and issuance of preferred shares, shares.
Fair market value percentage.
Fair value assumption expected life of up to (years).
Fair value assumption, percentage.
Fair value assumption, price.
Fair value assumption rate.
Former Microbot Israel Shareholders [Member]
From January 1, 2018 [Member]
Furniture And Office Equipment [Member]
General Manager and Chief Operating Officer [Member]
Hazel Gadot [Member]
Hezi Himelfarb [Member]
December 2016, And In May 2017 [Member]
Increase [Member]
Interested and Related Parties [Member]
Israeli Innovation Authority [Member]
June 2016 Agreements [Member]
Lease term.
Loan [Member]
MEDX Venture Group LLC [Member]
Merger Agreement [Member]
Microbot Israel [Member]
Net Sales Royalty Percentage
Number Of Stock Option Granted As Adjustment Of Reflect Merger.
Number of Warrant Exercisable, Period.
Office Lease Agreement [Member]
Officer Lease Agreement [Member].
Operating Loss Carryforwards, Expiration.
Outflow in connection with current assets and liabilities acquired in reverse recapitalization, net.
Placement agent fee.
Preferred Stock [Member]
Preferred A Shares Microbot Medical Ltd. Post-Merger [Member]
Preferred A Shares Microbot Medical Ltd. Pre-Merger [Member]
Prior to Decmber 31, 2016 [Member]
Prior to November 11, 2016 [Member]
Purchaser [Member].
Research Agreement [Member].
Research Equipment and Software [Member]
Revaluation of warrants.
Rights to acquire shares of common stock.
Securities Exchange Agreement [Member]
Securities Purchase Agreement [Member]
Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred Shares [Member]
Series A (2011) [Member]
Series A Two Thousand And Eleven One [Member].
Series A (2015) [Member]
Series A (2016) [Member]
Series A (2013) [Member]
Series A (2013) One [Member]
Series B (2016) [Member]
Significant Accounting Policies [Policy Text Block]
Stock Issued During Period Shares Cashless Exercise Of Warrants.
Stock Issued During Period Value Cashless Exercise Of Warrants.
Stock option merger retroactively adjusted exercise price per share.
Tax Act [Member]
Technician Research And Development Foundation Limited [Member]
Temporary Equity [Member]
Three Israeli Shareholders [Member]
From 2018 [Member]
2011 Series A Warrants [Member]
2015 [Member]
2014 [Member]
2017 Equity Incentive Plan [Member]
2017 [Member]
2016 [Member]
2016 Series A Warrants [Member]
Two Thousand Sixteen Series A and B Warrants [Member]
US Tax Authority [Member]
Unamortized Discount [Member]
Unaudited Interim Financial Statements [Policy Text Block]
Warrant calculation description.
Warrant Exercisable.
Two Thousand Thirteen To June Thirty Two Thousand Eighteen [Member]
Shares issued as consideration-vendor.
Preferred A Shares Microbot Medical Ltd. (Pre - Merger) [Member]
Preferred A Shares Microbot Medical Ltd. (Post - Merger) [Member]
Stock Issued During Period Value Effect Of Reverse Recapitalization.
Stock Issued During Period Shares Effect Of Reverse Recapitalization Shares.
Stock Issued During Period Value Transaction Costs Incurred In Reverse Recapitalization.
Stock Issued During Period Shares Transaction Costs Incurred In Reverse Recapitalization.
Extinguishment of convertible notes in exchange for preferred A shares.
Acquisition of a subsidiary in connection with reverse recapitalization.
Transaction costs incurred in reverse recapitalization.
Exercise of warrants issued upon conversion of notes.
Reverse recapitalization effect on equity.
Cash acquired in connection with reverse recapitalization.
General and administrative expenses [Text Block].
Transaction Costs [Policy Text Block]
Schedule of Property and Equipment Useful Lives [Table Text Block]
Schedule of General and Administrative Expense [Table Text Block]
Before Reverse Split [Member]
September 4, 2018 [Member]
September 4, 2018 [Member]
Microbot Israel [Member]
Percentage of severance award.
Common Stock Issued In Connection With Conversion Of Loan At Merger.
Number of common stock issued in prior to the merger.
Cancelled.
2013 Through 2017 [Member]
Cars Lease Agreement [Member]
Series A Convertible Preferred Stock [Member]
Net Loss Per Share Basic Diluted.
Amount of general and administrative expense related to public and investor relation.
The amount of expense provided in the period for government service fees.
NIS [Member]
Patent description.
Cost of materials used in services rendered by an entity during the reporting period.
Costs incurred and are directly related to generating maintenance revenues. Also includes cost of maintenance on client contracts.
Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.
Costs incurred and are directly related to generating maintenance revenues. Also includes cost of maintenance on client contracts.
Institutional Holder [Member]
Office Equipment [Member]
SeriesATwoThousandAndThirteenOneMember
SeptemberFourTwoThousandAndEighteenMember
MicrobotIsraelsMember
SeriesAConvertiblePreferredShareMember
IsraelNewShekelsMember
Assets, Current
Assets
Liabilities, Current
Liabilities, Noncurrent
Liabilities
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Interest and Debt Expense
Shares, Outstanding
Temporary Equity, Stock Issued During Period, Value, New Issues
Gain (Loss) on Extinguishment of Debt
SharesIssuedAsConsiderationVendor
Increase (Decrease) in Other Receivables
Net Cash Provided by (Used in) Operating Activities
Increase in Restricted Cash
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
TransactionCostsIncurredInReverseRecapitalization
OutflowInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
CashlessExerciseOfWarrants
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other
CashAcquiredInConnectionWithReverseRecapitalization
Earnings Per Share, Policy [Policy Text Block]
Research and Development Expense, Policy [Policy Text Block]
Long-term Debt, Gross
Debt Instrument, Unamortized Discount
DerivativeWarrantLiabilitiesBeginningBalance
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
RevenueFromGrant
OfficeAndMaintenanceExpenses
Other General and Administrative Expense
Interest Income (Expense), Nonoperating, Net
Foreign Currency Transaction Gain (Loss), before Tax
Costs and Expenses, Related Party
Due to Related Parties
Deferred Tax Assets, Valuation Allowance